Merck's diabetes-cholesterol pill gets FDA nod

Merck's new drug 'Juvisync,' which is a combination of two drugs Januvia and Zoco, is the first such pill to win approval of the U.S. health regulator.

“We are proud to bring forward a treatment option that can help these patients who need both glycemic and lipid therapy,” stated Barry J. Goldstein, M.D., Ph.D., vice president, Diabetes and Endocrinology, Merck.

According to FDA, nearly 20 million people in the United States suffer from type 2 diabetes, and many of them also have high cholesterol levels.

'Juvisync will be available at the same price as JANUVIA, approximately about $215 a month.